BioCentury | Feb 9, 2021
Management Tracks

Collins stepping down as Editas CEO, Mallon leaving Ironwood; plus Kite, Werewolf, Vedanta and more

...for cancer, hired Patrick McCall as CFO. He was VP of finance at Turnstone Biologics Inc.Vedanta Biosciences Inc....
...Staff [MERGED] Vedanta Biosciences Inc. [MERGED] Primmune Therapeutics [MERGED] Gilead [MERGED] Ironwood Pharmaceuticals Inc. [MERGED] Editas Medicine Gilead Sciences Inc. Editas Medicine Inc. Ironwood Pharmaceuticals Inc. Vedanta Biosciences Inc. Primmune...
...Primmune Therapeutics [MERGED] Gilead [MERGED] Ironwood Pharmaceuticals Inc. [MERGED] Editas Medicine Gilead Sciences Inc. Editas Medicine Inc. Ironwood Pharmaceuticals Inc. Vedanta Biosciences Inc. Primmune Therapeutics Inc. Vedanta Primmune...
BioCentury | Feb 2, 2021
Finance

Prophylactic antibacterials backed by CARB-X: Data Byte

...Vedanta Biosciences Inc., graduated from CARB-X in 2018 after completing Phase I testing for recurrent C. difficile infection. Vedanta...
BioCentury | Jan 13, 2021
Deals

Jan. 12 Quick Takes: $230M series B for Flagship’s ‘gene writer’ Tessera; plus Elucida, Vedanta, AbbVie-Dragonfly, Primmune

...invested $25 million in microbiome company Vedanta Biosciences Inc. as part of the Pfizer Breakthrough Growth Initiative. Vedanta...
...to start in 2021. Michael Vincent, CSO of Pfizer’s Inflammation & Immunology Research Unit, will join Vedanta’s...
BioCentury | Oct 17, 2020
Emerging Company Profile

Fed Bio: designing gut microbiomes with staying power and enhancing immune-modulating bacteria

...Therapeutics Inc. (NASDAQ:MCRB),  Finch Therapeutics Group Inc. and Vedanta Biosciences Inc....
...colitis. Seres’ includes ulcerative colitis and melanoma. Vedanta’s...
...are designed to persist in guts. Seres and Vedanta...
BioCentury | Apr 17, 2020
Product Development

Seeking safe microbiome therapies amid COVID-19 crisis

...or newly identified infectious agents," said Sue Dillon, CEO of Aro Biotherapeutics Co. and a Vedanta Biosciences Inc....
...stool believe their cell isolation processes protect their products from both known and unknown pathogens. Vedanta...
...testing for recurrent CDI. Targets ACE2 - Angiotensin-converting enzyme 2 Karen Tkach Tuzman, Associate Editor Seres Therapeutics Inc. Vedanta Biosciences Inc. Rebiotix...
BioCentury | Dec 12, 2019
Clinical News

PureTech’s Akili reports positive data for depression video game

...American College of Neuropsychopharmacology meeting on Wednesday. Other PureTech companies with news this week include Vedanta Biosciences Inc....
BioCentury | Sep 27, 2019
Emerging Company Profile

Chain: engineering microbial delivery to the colon

...molecules from their own microbiome discovery programs into Chain’s platform. Seres Therapeutics Inc. (NASDAQ:MCRB) and Vedanta Biosciences Inc....
BioCentury | Sep 23, 2019
Financial News

Sept. 23 Financial Quick Takes: Innate looks to add U.S. listing; plus Curamir's launch, Qihan Bio and Vedanta

...for preclinical R&D of its xenotransplantation technologies. Microbiome company Vedanta tops off $62.1M series C Vedanta Biosciences Inc....
...VE303, a Phase II candidate to treat recurrent Clostridium difficile infection. Hongjiang Li, Staff Writer VE416 VE800 VE303 Innate Pharma S.A. Vedanta Biosciences Inc. Curamir...
BioCentury | May 13, 2019
Financial News

May 13 Financial Quick Takes: Biotech trio update IPO plans, plus Vedanta, TreeFrog

...“Cortexyme’s First-Day Pop Leads IPO Quartet Amid Choppy Market” ). Microbiome company Vedanta raises $18.5M Vedanta Biosciences Inc....
...the total amount raised in the now closed round to $45.5 million (see "Microbiome Company Vedanta...
...EPAS1) - Endothelial PAS domain protein 1 Brian Moy, Assistant Editor Bicycle Therapeutics Ltd. Ideaya Biosciences Inc. Peloton Therapeutics Inc. Vedanta Biosciences Inc. TreeFrog...
BioCentury | Mar 15, 2019
Product Development

The microbiome universe in two maps

...programs. Companies have flooded into the space since early movers such as Seres Therapeutics Inc., Vedanta Biosciences Inc....
...SNIPR Biome ApS, Copenhagen, Denmark Symbiotix Biotherapies Inc., Boston, Mass. Synlogic Inc. (NASDAQ:SYBX), Cambridge, Mass. Vedanta Biosciences Inc....
...Biosciences Inc. Ferring Pharmaceuticals A/S Genetic Analysis A/S MaaT Pharma S.A. Osel Inc. Second Genome Inc. Seres Therapeutics Inc. Symbiotix Biotherapies Inc. Synlogic Inc. Vedanta Biosciences Inc. SNIPR...
Items per page:
1 - 10 of 61
BioCentury | Feb 9, 2021
Management Tracks

Collins stepping down as Editas CEO, Mallon leaving Ironwood; plus Kite, Werewolf, Vedanta and more

...for cancer, hired Patrick McCall as CFO. He was VP of finance at Turnstone Biologics Inc.Vedanta Biosciences Inc....
...Staff [MERGED] Vedanta Biosciences Inc. [MERGED] Primmune Therapeutics [MERGED] Gilead [MERGED] Ironwood Pharmaceuticals Inc. [MERGED] Editas Medicine Gilead Sciences Inc. Editas Medicine Inc. Ironwood Pharmaceuticals Inc. Vedanta Biosciences Inc. Primmune...
...Primmune Therapeutics [MERGED] Gilead [MERGED] Ironwood Pharmaceuticals Inc. [MERGED] Editas Medicine Gilead Sciences Inc. Editas Medicine Inc. Ironwood Pharmaceuticals Inc. Vedanta Biosciences Inc. Primmune Therapeutics Inc. Vedanta Primmune...
BioCentury | Feb 2, 2021
Finance

Prophylactic antibacterials backed by CARB-X: Data Byte

...Vedanta Biosciences Inc., graduated from CARB-X in 2018 after completing Phase I testing for recurrent C. difficile infection. Vedanta...
BioCentury | Jan 13, 2021
Deals

Jan. 12 Quick Takes: $230M series B for Flagship’s ‘gene writer’ Tessera; plus Elucida, Vedanta, AbbVie-Dragonfly, Primmune

...invested $25 million in microbiome company Vedanta Biosciences Inc. as part of the Pfizer Breakthrough Growth Initiative. Vedanta...
...to start in 2021. Michael Vincent, CSO of Pfizer’s Inflammation & Immunology Research Unit, will join Vedanta’s...
BioCentury | Oct 17, 2020
Emerging Company Profile

Fed Bio: designing gut microbiomes with staying power and enhancing immune-modulating bacteria

...Therapeutics Inc. (NASDAQ:MCRB),  Finch Therapeutics Group Inc. and Vedanta Biosciences Inc....
...colitis. Seres’ includes ulcerative colitis and melanoma. Vedanta’s...
...are designed to persist in guts. Seres and Vedanta...
BioCentury | Apr 17, 2020
Product Development

Seeking safe microbiome therapies amid COVID-19 crisis

...or newly identified infectious agents," said Sue Dillon, CEO of Aro Biotherapeutics Co. and a Vedanta Biosciences Inc....
...stool believe their cell isolation processes protect their products from both known and unknown pathogens. Vedanta...
...testing for recurrent CDI. Targets ACE2 - Angiotensin-converting enzyme 2 Karen Tkach Tuzman, Associate Editor Seres Therapeutics Inc. Vedanta Biosciences Inc. Rebiotix...
BioCentury | Dec 12, 2019
Clinical News

PureTech’s Akili reports positive data for depression video game

...American College of Neuropsychopharmacology meeting on Wednesday. Other PureTech companies with news this week include Vedanta Biosciences Inc....
BioCentury | Sep 27, 2019
Emerging Company Profile

Chain: engineering microbial delivery to the colon

...molecules from their own microbiome discovery programs into Chain’s platform. Seres Therapeutics Inc. (NASDAQ:MCRB) and Vedanta Biosciences Inc....
BioCentury | Sep 23, 2019
Financial News

Sept. 23 Financial Quick Takes: Innate looks to add U.S. listing; plus Curamir's launch, Qihan Bio and Vedanta

...for preclinical R&D of its xenotransplantation technologies. Microbiome company Vedanta tops off $62.1M series C Vedanta Biosciences Inc....
...VE303, a Phase II candidate to treat recurrent Clostridium difficile infection. Hongjiang Li, Staff Writer VE416 VE800 VE303 Innate Pharma S.A. Vedanta Biosciences Inc. Curamir...
BioCentury | May 13, 2019
Financial News

May 13 Financial Quick Takes: Biotech trio update IPO plans, plus Vedanta, TreeFrog

...“Cortexyme’s First-Day Pop Leads IPO Quartet Amid Choppy Market” ). Microbiome company Vedanta raises $18.5M Vedanta Biosciences Inc....
...the total amount raised in the now closed round to $45.5 million (see "Microbiome Company Vedanta...
...EPAS1) - Endothelial PAS domain protein 1 Brian Moy, Assistant Editor Bicycle Therapeutics Ltd. Ideaya Biosciences Inc. Peloton Therapeutics Inc. Vedanta Biosciences Inc. TreeFrog...
BioCentury | Mar 15, 2019
Product Development

The microbiome universe in two maps

...programs. Companies have flooded into the space since early movers such as Seres Therapeutics Inc., Vedanta Biosciences Inc....
...SNIPR Biome ApS, Copenhagen, Denmark Symbiotix Biotherapies Inc., Boston, Mass. Synlogic Inc. (NASDAQ:SYBX), Cambridge, Mass. Vedanta Biosciences Inc....
...Biosciences Inc. Ferring Pharmaceuticals A/S Genetic Analysis A/S MaaT Pharma S.A. Osel Inc. Second Genome Inc. Seres Therapeutics Inc. Symbiotix Biotherapies Inc. Synlogic Inc. Vedanta Biosciences Inc. SNIPR...
Items per page:
1 - 10 of 61